The 19th Silver Snake Awards of the Shanghai Health System have been announced: 39 outstanding young people stand out in technology | youth | health

Release time:Apr 14, 2024 21:22 PM

Today, the results of the 19th Silver Snake Awards were officially announced, with 22 outstanding medical youths winning the Silver Snake Awards and 17 medical youths receiving nomination awards. Mr. Shi Zhifeng from the Neurosurgery Department of Huashan Hospital affiliated with Fudan University and Mr. Liu Shen from the Orthopedics Department of Shanghai Sixth People's Hospital won the first prize of the Silver Snake Award this year; Their mentors, Professor Mao Ying from Huashan Hospital and Professor Fan Cunyi from the Sixth People's Hospital, were awarded the Special Honorary Award of the Silver Snake Award.

The Silver Snake Award is the highest honor award for young talents in the Shanghai Health System, established in 1989. This award is aimed at outstanding medical young people under the age of 40 in Shanghai and is selected every two years. For over 30 years, the Silver Snake Award has played an extremely important role in exploring and cultivating outstanding medical young talents in Shanghai, and batches of outstanding young people have stood out on this platform. As of now, 313 medical youth have received this honor, 29 first prize winners have received special honor awards from their mentors, and 323 have received nomination awards. Among the award-winning teams, 9 academicians, as well as a large number of renowned doctors and academic leaders, have been born, and some have even taken important leadership positions. These medical young people with both moral integrity and talent have become an important backbone of Shanghai's medical and health team.

Among the 39 winners of this year, 9 Chengdu has led projects or major projects funded by the National Natural Science Foundation of China. Some have published papers with high impact factors and high other citations in top international journals; Some have won national and provincial-level scientific and technological progress awards. They are brave in innovation, breaking through some major difficult and complex problems in clinical practice, and have obtained a total of 250 patent authorizations, including 85 invention patents. Many patents have been transformed and applied in clinical practice, resulting in very good social and economic benefits.

The winners of this year have demonstrated the following characteristics:

Aim at the forefront of medicine and promote clinical practice through scientific research. Dr. Shi Zhifeng from the Neurosurgery Department of Huashan Hospital specializes in neurotumors, especially malignant gliomas. He established the "Huashan Plan" for molecular classification of gliomas, elucidated the molecular characteristics of various subtypes of gliomas that have not been defined by the World Health Organization, and proposed a new viewpoint that "molecular classification is superior to WHO grading in prognosis judgment"; Develop a rapid molecular diagnostic system for gliomas based on artificial intelligence imaging omics technology, with a diagnostic time of only 3 minutes and an accuracy rate of up to 93%. Hosted 8 national and provincial level projects, published 32 SCI papers, and granted 8 invention patents.

Devote oneself to clinical research and innovation through inheritance. Liu Shen from the Orthopedics Department of the Sixth People's Hospital has inherited the "limb replantation" technology of the Sixth Hospital, completed more than a thousand surgeries such as limb/finger replantation and micro flap, promoting the transition from "limb preservation" to "functional preservation"; Establish new treatment techniques for "elbow joint adhesion" to improve comprehensive efficacy; Clarify the principles and mechanisms of prevention and treatment materials for tendon adhesion, and guide the development of new technologies and products. Received the second prize of National Science and Technology Progress Award and the first prize of Shanghai Science and Technology Progress Award, with 15 national patent authorizations and 5 conversions.

Exploring the high ground of basic research and achieving important academic achievements. Dr. Zou Qiang, a second prize winner from the School of Medicine of Shanghai Jiao Tong University and the Institute of Immunology of the city, focused on the metabolic regulation mechanism of tumor immune response and tolerance. Using molecular, cellular, biochemical, animal models, clinical samples, and other methods, he studied the key factors involved in regulating tumor immune metabolism and their mechanisms of action. He explored immunotherapy strategies for intervening in tumor immune metabolism to improve tumor immune response and achieved a series of important academic achievements, providing new targets and strategies for improving anti-tumor immune response. Representative works have been published in international professional journals such as Cell Metabolism and Molecular Cells.

The results of many applicants for second level hospitals in this year are also very impressive, such as Dr. Wu Wenguang, Deputy Chief Physician of the General Surgery Department of Jiading Central Hospital, who has unique insights into the diagnosis and treatment of difficult endoscopic retrograde cholangiopancreatography after liver transplantation, digestive tract reconstruction, pediatric, and critically ill patients. He led a team to complete more than 2000 ERCPs per year, creating the first day ward ERCP diagnosis and treatment process and ERCP specialized day ward in Shanghai, achieving rapid diagnosis and treatment of patients and postoperative recovery, shortening patient hospitalization time, and saving hospitalization costs. Received the first prize of the Ministry of Education Science and Technology Progress Award, the Shanghai Medical Science and Technology Award Youth Award, and the second prize of the Huaxia Medical Science and Technology Award. In addition, many applicants not only have excellent moral and technical skills, but also stand up and fulfill their mission when the fight against the epidemic is most needed. Dr. Zhao Linghao, Deputy Chief Physician of the Department of Hepatology at Dongfang Hepatobiliary Surgery Hospital, postponed his wedding and volunteered to go to Wuhan to fight day and night on the front line of Huoshenshan Hospital. He was awarded the titles of "Huoshenshan Medical Star" and "Epidemic Pioneer".

These respected and approachable medical youths are the undisputed protagonists of the award ceremony. They received honors and felt more responsibility and responsibility. Wen Daxiang, Secretary of the Party Group and Director of the Municipal Health Commission, said, "Winning an award is an important milestone in everyone's medical career and a new starting point. Achievements belong to the past, and we still need to work hard in the future. We hope that the winners will continue to motivate and motivate themselves, and strive towards higher goals."

The "Silver Snake Award" selection activity is organized by the Shanghai Health System Youth Talent Award Foundation under the guidance of the Shanghai Municipal Health Commission, and jointly organized by the Shanghai Medical Insurance Association, Wenhui Daily, Shanghai Education TV Station, and Shanghai Pharmaceutical Holdings Co., Ltd.

Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer
Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer

Immunotherapy has been proven to achieve significant therapeutic effects in various solid tumors. However, for pancreatic cancer, known as the "king of cancer", immunotherapy has been ineffective. On August 4, Professor Yu Xianjun, Dean of the Cancer Hospital Affiliated to Fudan University, and Shi Si, Associate Professor of Pancreatic Surgery released a research achievement, which first found the key role of cysteine rich protein 1 in shaping the immunosuppressive microenvironment of pancreatic cancer, filled the gap in the research field of immunosuppressive microenvironment of pancreatic cancer, and provided a theoretical basis for precise immunotherapy of pancreatic cancer patients. Ductal adenocarcinoma of the pancreas is the main type of pancreatic cancer, accounting for about 90% of all pancreatic cancer. Due to its high malignancy and poor treatment effectiveness, pancreatic ductal adenocarcinoma has always been one of the most malignant tumors. In recent years, the level of surgical techniques and comprehensive treatment has been achieved

A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare
A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare

A 14-year-old girl has been experiencing symptoms such as protruding pupils, incomplete eye closure, corneal injury, restricted eye movement, and overall fatigue for several years. The physical discomfort and facial abnormalities caused by eye diseases have made her increasingly reticent, and her temperament is vastly different from before. At the Ophthalmology Department of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the pupil has been diagnosed with a rare thyroid ophthalmopathy combined with myasthenia gravis, which requires prompt treatment. However, considering the young age of the pupil, conventional hormone and radiation therapy cannot be used. Therefore, Zhou Huifang, Deputy Director of Ophthalmology and thyroid ophthalmology expert, has developed a targeted drug combined with surgical treatment plan for it, and targeted drug treatment will be performed first. Three months ago, I was hospitalized for one week with mydriasis and received intravenous targeted drug treatment. Afterwards, I went home for observation and followed up on time

The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease
The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease

According to the Statistics of Chinese Dry Eye Expert Consensus, the incidence rate of dry eye in China is about 21%~30%, and it is estimated that there are at least 300 million patients nationwide. The Dry Eye Diagnosis and Treatment Studio of Shanghai Eye Disease Prevention and Treatment Center was officially launched today. In the future, the studio will continuously improve the dry eye diagnosis and treatment standards, and form standardized diagnosis and treatment concepts and service models. Suitable technologies will be promoted to the community, allowing residents to enjoy convenient dry eye diagnosis and treatment services at their doorstep. Executive Dean and Party Secretary Gao Wei stated that this is also one of the livelihood service measures recently launched by the hospital around high-quality development and meeting the needs of the people. It is reported that dry eye syndrome is a chronic ocular surface disease caused by multiple factors. The instability of the tear film or imbalance of the ocular surface microenvironment caused by abnormal quality, quantity, and dynamics of tears can be accompanied by ocular surface inflammatory reactions, tissue damage, and nerve abnormalities, resulting in various discomforts in the eyes

The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice
The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice

The International Dental Implant Consensus Report, jointly written by the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine and renowned universities in the field of dentistry such as Harvard University, University of Zurich, University of Gothenburg, Columbia University, and University of Frankfurt, has recently been jointly published in top journals in the field of dentistry, including Clinical Periodontology and Clinical Dental Implant Research. This consensus has for the first time established an internationally unified core set of indicators for evaluating the clinical effectiveness of dental implants, covering the five key areas of the field of dental implants. It is of milestone significance for carrying out standardized clinical diagnosis, treatment, and research on dental implants. The core evaluation indicators determined by this consensus will become an important benchmark for scholars in the field of dental implants worldwide to conduct high-quality research. The consensus is composed of 8 top international experts in the field of oral implantation

Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases
Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases

Recently, Catherine, a British girl born in the 1990s, received autologous peripheral blood hematopoietic stem cell transfusion at the Cancer Center of Shanghai Jiahui International Hospital, and was successfully discharged from the warehouse. She is now on her way back to China after being discharged from the hospital. She is also the first patient at Shanghai Jiahui International Hospital to complete relevant treatments. In 2019, Catherine was diagnosed with Hodgkin's lymphoma in the UK, and after treatment, the disease completely improved. During her work and life in China in 2021, she went to seek medical attention due to multiple enlarged lymph nodes. Pathological biopsy confirmed a recurrence of Hodgkin's lymphoma, and through combined targeted drug treatment, her condition was temporarily under control. Last year in the second half of the year, when the disease recurred, the girl began to use immunotherapy combined with targeted drugs for treatment. Expert evaluation suggests that for young patients with hematological tumors, the risk of recurrence is high and treatment difficulty is increasing in the future. Autologous hematopoietic stem cell therapy is recommended